CD123 Redirected Autologous T Cells for AML

Summary

Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myeloid Leukemia (AML) subjects.

Timeline

Start

2015-12

Primary completion

2016-08-26

Completion

2016-11-18

Drugs

Indications